Cellular OncologyPub Date : 2026-08-25DOI: 10.1007/s13402-026-01282-7
Runtian Li, Huanye Mo, Lei Zhang, Qingguang Liu, Kangsheng Tu
{"title":"OTUD1-mediated deubiquitination stabilizes SLC7A11 to suppress ferroptosis in hepatocellular carcinoma.","authors":"Runtian Li, Huanye Mo, Lei Zhang, Qingguang Liu, Kangsheng Tu","doi":"10.1007/s13402-026-01282-7","DOIUrl":"10.1007/s13402-026-01282-7","url":null,"abstract":"<p><strong>Background: </strong>Evasion of ferroptosis has been increasingly recognized as an important mechanism underlying lenvatinib resistance in hepatocellular carcinoma (HCC). However, the roles of deubiquitinating enzymes in ferroptosis regulation and the post-translational control of key ferroptosis regulators in HCC remain poorly understood.</p><p><strong>Methods: </strong>Public lenvatinib resistance-related and ferroptosis-related datasets were analyzed to identify candidate deubiquitinating enzymes associated with HCC therapeutic resistance and ferroptotic stress. Loss- and gain-of-function assays were performed to evaluate the effects of OTUD1 on lenvatinib sensitivity, erastin-induced ferroptosis, and HCC cell growth. Subcutaneous xenograft and orthotopic tumor models were used to assess the role of OTUD1 in tumor growth and ferroptosis resistance in vivo. Western blotting, RT-qPCR, co-immunoprecipitation, cycloheximide chase, MG132 rescue, ubiquitination, SLC7A11 rescue, and ERK1/2 pathway modulation assays were conducted to investigate the underlying mechanism. Clinical HCC specimens and public datasets were analyzed to determine OTUD1 expression and its association with patient prognosis.</p><p><strong>Results: </strong>OTUD1 was identified as a gene associated with lenvatinib resistance in HCC. Knockdown of OTUD1 sensitized HCC cells to lenvatinib, and this effect was abolished by ferroptosis inhibition. OTUD1 knockdown enhanced ferroptosis in HCC cells, whereas OTUD1 overexpression suppressed it. Moreover, OTUD1 promoted HCC growth and conferred ferroptosis resistance in mice. Mechanistically, OTUD1 interacted with solute carrier family 7 member 11 (SLC7A11) and removed its K48-linked polyubiquitin chains, thereby stabilizing SLC7A11 protein levels. In addition, ERK1/2-dependent phosphorylation of OTUD1 at Ser216 strengthened its interaction with SLC7A11, further enhancing SLC7A11 stability and promoting ferroptosis resistance. Analysis of clinical samples and public datasets further revealed that OTUD1 was upregulated in HCC tissues and correlated with poor prognosis.</p><p><strong>Conclusions: </strong>Our findings identify the ERK1/2-OTUD1-SLC7A11 axis as a key mechanism mediating ferroptosis resistance in HCC. These results suggest that OTUD1 may serve as a potential therapeutic target for HCC.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 5","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149058624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"KLF5-SLC2A1 axis promotes intrahepatic cholangiocarcinoma progression via SPP1 + macrophage-mediated microenvironment remodeling.","authors":"Hui Li, Ying Zhu, Zhixiang Hu, Changjing Huang, Zhouyu Ning, Zhiqiang Meng","doi":"10.1007/s13402-026-01275-6","DOIUrl":"https://doi.org/10.1007/s13402-026-01275-6","url":null,"abstract":"<p><strong>Background: </strong>Tumor metabolic reprogramming shapes the tumor microenvironment (TME) and modulates anti-tumor immunity, yet the interplay between metabolic adaptation and immune regulation in intrahepatic cholangiocarcinoma (ICC) remains unclear. We investigated the role of the glucose transporter GLUT1 (SLC2A1) as a potential immunometabolic regulator in ICC.</p><p><strong>Methods: </strong>We integrated bulk and single-cell transcriptomics with multi-omics profiling, and performed in vitro and in vivo functional validation. Pharmacologic inhibition was achieved using the selective GLUT1 inhibitor BAY-876. Single-cell analyses and tumor cell-macrophage co-culture assays were used to characterize immune composition and macrophage polarization. Mechanistic studies probed signaling pathways linking glucose transport to cytokine release and macrophage activation.</p><p><strong>Results: </strong>GLUT1 expression was increased in malignant cholangiocytes and associated with worse prognosis. Single-cell data revealed stage-dependent GLUT1 dynamics, peaking at intermediate tumor states and declining during late-stage metabolic shifts toward lipid and MYC-driven programs. BAY-876 suppressed tumor cell proliferation and reduced tumor burden in preclinical models. High GLUT1 abundance correlated with an immune-suppressed TME reduced overall immune infiltration and predominance of M2-like macrophages, whereas GLUT1 inhibition increased tumor cell release of TNFα, activated NF-κB signaling in macrophages, and promoted M1-like polarization. Mechanistically, GLUT1 blockade activated p53 signaling and enhanced ADAM17 maturation, facilitating proteolytic release of TNFα and thereby engaging a p53/ADAM17/TNFα/NF-κB axis that links glucose transport to macrophage phenotype.</p><p><strong>Conclusions: </strong>These data nominate GLUT1 as an immunometabolic regulator in ICC and provide a rationale to evaluate GLUT1-directed strategies, alone or combined with immune-modulatory agents, to overcome metabolic heterogeneity and remodel the TME.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cellular OncologyPub Date : 2026-08-18DOI: 10.1007/s13402-026-01277-4
Xianfu Wei, Yan Zhang, Zhipeng Wang, Feiyue Lin, Qiang Yang, Long Chen
{"title":"A chemoresistance- and lactylation-related lncRNA prognostic signature uncovers LINC01976/LDHA/lactylation regulatory axis in osteosarcoma chemoresistance.","authors":"Xianfu Wei, Yan Zhang, Zhipeng Wang, Feiyue Lin, Qiang Yang, Long Chen","doi":"10.1007/s13402-026-01277-4","DOIUrl":"https://doi.org/10.1007/s13402-026-01277-4","url":null,"abstract":"<p><strong>Background: </strong>Osteosarcoma represents the most frequent primary malignant bone neoplasm in adolescents, with chemoresistance remaining a pivotal barrier to clinical cure and prognosis. Long non-coding RNAs (lncRNAs) are crucial epigenetic modulators governing malignant tumor progression, whereas lactylation constitutes a newly identified metabolic-epigenetic modification driving cancer chemoresistance. Nevertheless, the clinical significance and biological functions of chemoresistance- and lactylation-related lncRNAs (CRLR-lncRNAs) in osteosarcoma chemoresistance remain elusive.</p><p><strong>Methods: </strong>Osteosarcoma transcriptomic, clinical data, and scRNA-seq profiles were obtained from the TARGET database and the GSE152048 cohort, respectively. CRLR-lncRNAs were screened via Pearson correlation between lncRNAs and chemoresistance- and lactylation-related DEGs. A CRLR-lncRNA prognostic signature was constructed using LASSO and multivariate Cox regression, and validated by stratified survival analysis and nomogram. Functional enrichment, immune infiltration, drug sensitivity, tumor mutational burden (TMB), and Single-cell RNA-sequencing (scRNA-seq) analyses were further conducted. In vitro and in vivo assays were conducted to clarify the role and mechanism of the core lncRNA LINC01976 in osteosarcoma chemoresistance.</p><p><strong>Results: </strong>Using the TARGET dataset, a novel prognostic signature consisting of 6 CRLR-lncRNAs was constructed and validated, exhibiting high accuracy in predicting 1-, 3-, and 5-year overall survival of osteosarcoma patients. It served as an independent prognostic factor superior to conventional clinicopathological indicators, with robust prognostic value across clinical subgroups and the capacity for individualized survival prediction. Functional enrichment analysis revealed enrichment in extracellular matrix remodeling, oncogenic signaling pathways, and immune-related processes. The signature effectively stratified patients into immune-active low-risk and immunosuppressive high-risk subgroups with distinct tumor immune microenvironments, TMB levels, and drug sensitivity. ScRNA-seq analysis confirmed the heterogeneous distribution and differential expression of signature lncRNAs between chemo-sensitive and chemo-resistant lesions. Notably, lactylation-related LINC01976 was upregulated in chemoresistant osteosarcoma and correlated with poor prognosis. Mechanistically, LINC01976 promotes cisplatin resistance in osteosarcoma both in vitro and in vivo by enhancing LDHA-dependent lactylation; specifically, LINC01976 upregulates LDHA expression, increasing intracellular lactate production and lysine lactylation levels alongside histone H3K18la, thus forming a LINC01976/LDHA/lactylation regulatory axis to further reinforce cisplatin resistance.</p><p><strong>Conclusion: </strong>The novel CRLR-lncRNA signature effectively predicts the prognosis, immune landscape, and chemosensitivity of osteos","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cellular OncologyPub Date : 2026-08-17DOI: 10.1007/s13402-026-01276-5
Huimin Wang, Lin Zhou, Jie Chen, Chunlei Zhou, Yang Li, Jiangbo Liu, Hong Mu
{"title":"EEF1G promotes cancer-associated fibroblast activation and drives lung cancer metastasis.","authors":"Huimin Wang, Lin Zhou, Jie Chen, Chunlei Zhou, Yang Li, Jiangbo Liu, Hong Mu","doi":"10.1007/s13402-026-01276-5","DOIUrl":"10.1007/s13402-026-01276-5","url":null,"abstract":"<p><strong>Background: </strong>Cancer-associated fibroblasts (CAFs) are crucial for tumor microenvironment remodeling and tumor metastasis. Eukaryotic elongation factor 1 gamma (EEF1G) is aberrantly expressed in many tumors, but its role in lung cancer metastasis, particularly via exosome-mediated CAF activation, remains unclear. This study investigated EEF1G's mechanism in lung cancer metastasis through exosome-induced tumor-stroma interactions.</p><p><strong>Methods: </strong>We performed bioinformatics analyses, single-cell RNA sequencing, and in vitro experiments (cell culture, exosome isolation, Western blot, qRT-PCR, and immunofluorescence) to characterize the function of EEF1G. A tumor-fibroblast co-culture system and in vivo metastasis models validated the EEF1G-exosome-CAF axis and associated signaling.</p><p><strong>Results: </strong>EEF1G was overexpressed in lung cancer tissues and exosomes, which correlated with poor prognosis and CAF infiltration. EEF1G promoted the proliferation, migration, and invasion of lung cancer cells. Mechanistically, tumor cells transferred exosomal EEF1G to fibroblasts, inducing CAF transformation via the activation of the NF-κB/ROS pathway, increased mitochondrial activity, and IL-6 secretion. Subsequently, CAF-derived IL-6-rich exosomes activated STAT3 in tumor cells, enhancing invasiveness. In vivo experiments confirmed that this exosome-mediated bidirectional communication robustly facilitates lung cancer metastasis.</p><p><strong>Conclusion: </strong>This study elucidates a novel EEF1G exosome-mediated pathway that activates CAFs, establishing a pro-oncogenic feedback network. We emphasize the critical NF-κB/ROS/IL-6/STAT3 signaling axis in tumor-stroma interactions, offering potential therapeutic targets for lung cancer.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13755296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeting PRMT5 to reshape the immune microenvironment and reverse Trop2 ADC resistance in triple-negative breast cancer.","authors":"Jing Kong, Minghui Li, Yidi Wang, Mengxuan Li, Huimin Meng, Jiajun Ding, Jing Fan, Ting Wang","doi":"10.1007/s13402-026-01269-4","DOIUrl":"10.1007/s13402-026-01269-4","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) patients often develop resistance to Trop2 antibody-drug conjugate (ADC), and plasmacytoid dendritic cell (pDC) dysfunction is associated with poor prognosis in TNBC, but the underlying mechanism linking these two phenomena remains unclear.</p><p><strong>Methods: </strong>The immune cell infiltration and prognosis of TNBC were analyzed through the TIMER database. Sacituzumab Govitecan (SG)-resistant MDA-MB231 cells and xenograft tumor models were established, and the function of pDC was regulated with CpG or anti-BDCA-2. The relationship between Protein arginine methyltransferase 5 (PRMT5) and immune cell infiltration was predicted by the Xiantao academic analysis. CCK-8, plate cloning, EdU and other experiments were used to detect cell functions. The functions of pDC were detected by flow cytometry and ELISA experiments. Besides, IP and IB experiments were implemented to detect the ubiquitination level of interferon regulatory factor 3 (IRF3) and the methylation level of midline 2 (MID2), and the protein interactions were verified through the Co-IP experiment.</p><p><strong>Results: </strong>TNBC tissues resistant to SG showed reduced pDC infiltration and impaired function, associated with downregulation of IRF3. PRMT5 was highly expressed in the cytoplasm of SG-resistant TNBC cells and negatively correlated with pDC cell infiltration. PRMT5 promoted MID2 methylation to induce the ubiquitination and degradation of IRF3. Moreover, silencing PRMT5 activated pDCs, reversed CD8<sup>+</sup> T cell suppression, and enhanced the sensitivity of drug-resistant TNBC cells to SG in vitro and in vivo.</p><p><strong>Conclusion: </strong>Targeting PRMT5 reshapes the immune microenvironment by restoring pDC function via the MID2-IRF3 axis, providing a promising strategy to reverse SG resistance in TNBC.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genomic landscape of EGFR-TKI resistance: from known mechanisms to unknown resistance.","authors":"Songchen Zhao, Fei Zhou, Wenshuai Chen, Shuchun Wang, Caicun Zhou","doi":"10.1007/s13402-026-01253-y","DOIUrl":"10.1007/s13402-026-01253-y","url":null,"abstract":"<p><strong>Purpose: </strong>Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) serve as the standard first-line therapy for advanced EGFR-mutant non-small-cell lung cancer (NSCLC). However, resistance inevitably restricts their efficacy. Although well-documented acquired resistance mechanisms have been extensively characterized, approximately 30% of patients with EGFR-TKI resistance still present with unknown resistance (UR) mechanisms, and the driving factors behind primary resistance remain inadequately understood.</p><p><strong>Methods: </strong>In this study, we conducted a large-scale, retrospective cohort study, performing target-capture deep sequencing (>400 genes) on 928 samples from 745 EGFR-TKI-resistant and 183 TKI-naïve EGFR-mutant NSCLC patients.</p><p><strong>Results: </strong>The molecular landscape of EGFR-TKI resistance was systematically characterized. In the resistance cohort, 68.72% (512/745) harbored known resistance (KR) mechanisms, while 31.28% (233/745) were classified as UR. The landscape of KR was significantly influenced by EGFR-TKI generation. First-line third-generation TKI resistance demonstrated fewer EGFR-dependent events compared to first-generation TKIs (p < 0.01) and more RTK and PI3K-AKT-mTOR (PAM) pathway alterations (p < 0.05). In the UR cohort, pathway analysis revealed unique enrichment of atypical pathways, most notably ATP-dependent chromatin remodeling pathways. Differential gene analysis identified significant enrichment of MYC, BRCA1, EPHB, and PTPRD in the UR subgroup. To investigate primary resistance, we found that baseline IKZF1 amplification was significantly enriched in patients with short time-to-treatment-failure (TTF) and correlated with significantly poorer outcomes (HR = 3.02, 95% CI 1.32-6.90; log-rank p = 0.004).</p><p><strong>Conclusions: </strong>This study provides a comprehensive real-world landscape of EGFR-TKI resistance, demonstrating distinct mechanisms influenced by TKI generation. ATP-dependent chromatin remodeling was identified as a distinctive pathway feature of unknown resistance, and baseline IKZF1 amplification emerged as a candidate biomarker of EGFR-TKI primary resistance. These findings suggest that epigenetic dysregulation may be a critical driver of both unknown and primary resistance to EGFR-TKIs.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cellular OncologyPub Date : 2026-08-03DOI: 10.1007/s13402-026-01270-x
Hongyan Yu, Jie Wang, Yongchen Ji, Xiaofang Liu, Mingxu Xie, Chun Yin Lo, Wenhan Cao, Huazhong Zhou, Xiaoxue Li, Xiaoling Huang, Liwen Jiang, Xiaoqiong Gu, Xiangqi Meng, Xiaoqiang Yao
{"title":"MCOLN2 (Mucolipin-2) promotes autophagy to confer Adriamycin resistance in breast cancer by regulating mTOR degradation.","authors":"Hongyan Yu, Jie Wang, Yongchen Ji, Xiaofang Liu, Mingxu Xie, Chun Yin Lo, Wenhan Cao, Huazhong Zhou, Xiaoxue Li, Xiaoling Huang, Liwen Jiang, Xiaoqiong Gu, Xiangqi Meng, Xiaoqiang Yao","doi":"10.1007/s13402-026-01270-x","DOIUrl":"10.1007/s13402-026-01270-x","url":null,"abstract":"<p><strong>Background: </strong>Adriamycin is a cornerstone chemotherapeutic agent for advanced breast cancer, but its efficacy is frequently compromised by chemoresistance, a process in which macroautophagy is critically involved. However, the underlying mechanisms driving this autophagy-mediated resistance remain poorly understood.</p><p><strong>Methods: </strong>Clinical data from patients with breast cancer who underwent chemotherapy were collected and the expression of MCOLN2 in tumor tissues was assessed. Using Adriamycin-resistant MCF-7/ADM cells and their parental MCF-7 cells, we investigated the role of MCOLN2 in regulating autophagic flux and mediating drug resistance. Key findings were further validated using an in vivo xenograft model.</p><p><strong>Results: </strong>MCOLN2 expression was significantly upregulated in Adriamycin-resistant MCF-7/ADM cells and chemoresistant patient samples, where high levels correlated with poor prognosis. Knockdown of MCOLN2 sensitized MCF-7/ADM cells to Adriamycin both in vitro and in vivo, whereas its overexpression conferred resistance in parental MCF-7 cells. Mechanistically, MCOLN2 promoted autophagy, as evidenced by increased LC3-II levels and autophagosome formation. This pro-autophagic effect was mediated by MCOLN2-induced destabilization and lysosomal degradation of mTOR. Consequently, pharmacological or genetic inhibition of autophagy effectively reversed the MCOLN2-driven chemoresistance.</p><p><strong>Conclusion: </strong>The MCOLN2-mTOR-autophagy axis has a critical role in the development of therapeutic resistance to Adriamycin in breast cancer. Targeting MCOLN2 could be a promising therapeutic strategy to overcome Adriamycin resistance in breast cancer patients.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeting RPRD1B overcomes chemoresistance in gastric cancer by suppressing the TOPBP1-mediated DNA damage repair pathway.","authors":"Jian Sheng, Jianghua Li, Chenxi Cao, Xiaorong Liu, Chunhua He, Mingjian Fei, Bin Wu, Xiangli Li, Chundong Hu, Shumin Liu, Yahui Lv","doi":"10.1007/s13402-026-01227-0","DOIUrl":"10.1007/s13402-026-01227-0","url":null,"abstract":"<p><strong>Background: </strong>Despite the widespread adoption of 5-fluorouracil (5-FU)-based regimens as first-line therapy for gastric cancer, a substantial number of patients develop innate or acquired resistance, highlighting the critical need to identify its underlying molecular drivers. RPRD1B (CREPT), a gene frequently overexpressed in GC, has been clinically associated with advanced tumor stage and poor prognosis. Functionally, RPRD1B promotes aggressive tumorigenic phenotypes by accelerating cell-cycle progression, potentiating proliferative signaling, and enhancing the migratory and invasive capacities of cancer cells. However, its functional role in mediating chemotherapy resistance has not been elucidated.</p><p><strong>Methods: </strong>We established 5-FU-resistant gastric cancer cell lines (from AGS/MGC803 parents via stepwise drug exposure) to study RPRD1B's mechanism, and developed an AAV-based system to therapeutically target RPRD1B to overcome 5-FU resistance.</p><p><strong>Results: </strong>In this study, we demonstrated that GC patients with high tumor expression of RPRD1B (CREPT) exhibited a poor response to 5-fluorouracil (5-FU)-based chemotherapy. Furthermore, RPRD1B expression was positively correlated with the expression of TOPBP1, a critical DNA damage response and repair effector. Mechanistically, RPRD1B transcriptionally upregulates TOPBP1 by recruiting RNA polymerase II to its promoter, thereby enhancing DNA damage repair. Using an AAV-delivered shRNA to knockdown RPRD1B in a nude mouse xenograft model, we effectively overcame 5-FU resistance in gastric tumors in vivo.</p><p><strong>Conclusions: </strong>Our findings identify RPRD1B as a promising therapeutic target for reversing chemoresistance in gastric cancer.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 3","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148653005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cellular OncologyPub Date : 2026-07-30DOI: 10.1007/s13402-026-01268-5
Chaochao Zhang, Ruihuan Gan, Limei Wang, Qiuling Chen, Yuxiang Yan, Youguang Lu, Dali Zheng, Ke Zheng
{"title":"P4HA2 mediates hypoxia-induced collagen remodeling to promote tumor progression in head and neck squamous cell carcinoma.","authors":"Chaochao Zhang, Ruihuan Gan, Limei Wang, Qiuling Chen, Yuxiang Yan, Youguang Lu, Dali Zheng, Ke Zheng","doi":"10.1007/s13402-026-01268-5","DOIUrl":"10.1007/s13402-026-01268-5","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigated the clinical significance, regulatory mechanisms, and functional roles of Prolyl 4-Hydroxylase Subunit Alpha 2 (P4HA2) in head and neck squamous cell carcinoma (HNSCC), focusing on its involvement in hypoxia-driven extracellular matrix (ECM) remodeling and tumor progression.</p><p><strong>Methods: </strong>Immunohistochemical (IHC) analysis was performed on 108 clinical HNSCC specimens to evaluate the expression of P4HA2 and Hypoxia-Inducible Factor-1 Alpha (HIF-1α) and their association with patient prognosis. These clinical findings were further validated using bioinformatic data from public cohorts. The transcriptional regulation of P4HA2 by HIF-1α under hypoxic conditions was investigated via chromatin immunoprecipitation (ChIP). Functional assays, including assessments of P4HA2's dependency on its essential cofactor vitamin C, were conducted in HNSCC cell lines to evaluate cell proliferation, migration, and invasion in vitro. The role of P4HA2 in tumor growth and microenvironmental remodeling in vivo was examined using xenograft mouse models.</p><p><strong>Results: </strong>P4HA2 and HIF-1α were upregulated in HNSCC and associated with poor prognosis. Hypoxia-induced HIF-1α directly activated P4HA2 transcription. P4HA2 promoted collagen deposition and ECM remodeling, facilitating HNSCC cell proliferation, migration, and invasion, with its collagen-producing effects enhanced by vitamin C. In vivo, P4HA2 overexpression accelerated tumor growth, accompanied by enhanced HIF-1α signaling and collagen production.</p><p><strong>Conclusion: </strong>P4HA2 is a key effector of the hypoxia/HIF-1α axis, driving collagen remodeling to promote HNSCC progression, suggesting its potential as a therapeutic target.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}